<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0001013'>Eruptive xanthomas</z:hpo> in adults are usually indicative of chylomicronemia </plain></SENT>
<SENT sid="1" pm="."><plain>Although <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> is the most common secondary cause of chylomicronemia, which is designated as diabetic <z:mp ids='MP_0001548'>lipemia</z:mp>, the clinical characteristics of <z:mp ids='MP_0002055'>diabetes</z:mp> with regard to development of <z:mp ids='MP_0003692'>xanthomas</z:mp> are not well defined </plain></SENT>
<SENT sid="2" pm="."><plain>In this paper, we describe a young female who displayed <z:hpo ids='HP_0001013'>eruptive xanthomas</z:hpo> as an initial manifestation of diabetic <z:mp ids='MP_0001548'>lipemia</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>The patient was a 20-year-old female with a body mass index of 18.9 kg/m2 and Marfanoid appearance </plain></SENT>
<SENT sid="4" pm="."><plain>Her past history was unremarkable, except for <z:hpo ids='HP_0001643'>patent ductus arteriosus</z:hpo> and <z:hpo ids='HP_0001256'>mild mental retardation</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>She was admitted to our division for <z:hpo ids='HP_0001013'>eruptive xanthomas</z:hpo> on the extremities and marked <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> (random <z:chebi fb="105" ids="17234">glucose</z:chebi>, 520 mg/dl) and <z:hpo ids='HP_0002155'>hypertriglyceridemia</z:hpo> (6880 mg/dl) </plain></SENT>
<SENT sid="6" pm="."><plain>She was diagnosed with Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> based on the positive family history of <z:mp ids='MP_0002055'>diabetes</z:mp>, residual secretory capacity of insulin, and absence of autoantibodies related to Type 1 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="7" pm="."><plain>Based on the increase in the concentrations of both chylomicrons and <z:chebi fb="0" ids="39027">very low density lipoproteins</z:chebi>, type V <z:hpo ids='HP_0010980'>hyperlipoproteinemia</z:hpo> was diagnosed </plain></SENT>
<SENT sid="8" pm="."><plain>After the initiation of insulin therapy, both <z:hpo ids='HP_0002155'>hypertriglyceridemia</z:hpo> and <z:hpo ids='HP_0001013'>eruptive xanthomas</z:hpo> subsided, without administering any <z:chebi fb="0" ids="35679">hypolipidemic agents</z:chebi> </plain></SENT>
<SENT sid="9" pm="."><plain>Minimal model analysis of a frequently sampled intravenous <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance test revealed severe <z:hpo ids='HP_0000855'>insulin resistance</z:hpo>, despite the absence of <z:hpo ids='HP_0001513'>obesity</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>Post-<z:chebi fb="5" ids="28304">heparin</z:chebi> <z:chebi fb="1" ids="6495">lipoprotein</z:chebi> lipase (LPL) activity was moderately decreased, and common mutations in the LPL gene were not demonstrated by genetic screening </plain></SENT>
<SENT sid="11" pm="."><plain>The <z:chebi fb="0" ids="39015">apolipoprotein</z:chebi> E phenotype was E4/4, which is known to be associated with type V <z:hpo ids='HP_0010980'>hyperlipoproteinemia</z:hpo> </plain></SENT>
<SENT sid="12" pm="."><plain>Hypoadiponectinemia of 1.7 microg/ml was also revealed, which may, in part, account for the <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> and decreased LPL activity </plain></SENT>
<SENT sid="13" pm="."><plain>In conclusion, the clustering of <z:chebi fb="0" ids="39015">apolipoprotein</z:chebi> E4/4 and hypoadiponectinemia, in addition to <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> and poor glycemic control, might have resulted in <z:hpo ids='HP_0002155'>hypertriglyceridemia</z:hpo> with eruptive <z:hpo ids='HP_0000991'>xanthomatosis</z:hpo> in this subject </plain></SENT>
</text></document>